title: Hemofiltration for cytokine-driven illnesses: the mediator delivery hypothesis.
abstract: Hemofiltration is evolving as an adjunctive therapy for sepsis and other forms of systemic inflammation. Designed as a substitute for lost renal function, it is sometimes employed prior to the onset of renal failure to facilitate the nonspecific clearance of pro-inflammatory mediators. Prevailing theories suggest that hemofiltration attenuates the immune response when a threshold amount of excess cytokine is removed at the semi-permeable membrane. In this article we introduce an alternative hypothesis, in which hemofiltration exerts its effect by reinvigorating lymphatic flow and function. Crystalloid "replacement" solution, as much as 48 to 72 liters daily, is infused to restore intravascular volume lost through production of ultrafiltrate. Partial redistribution into interstitium and lymph mobilizes inflammatory mediators and other proteins, cellular byproducts, excessive ground matrix, fragments of apoptotic cells and free DNA. These substances are then metabolized, scavenged or cleared at multiple sites, including the reticuloendothelial system, liver, kidney, erythrocyte, and hemofilter.
authors.affiliation: Division of Pediatric Critical Care Medicine, Stanford University, 750 Welch Road Suite 315, Palo Alto, CA 94304, USA. jdicarlo@stanford.edu
authors.forename: J V
authors.initials: JV
authors.lastname: Di Carlo
authors.forename: S R
authors.initials: SR
authors.lastname: Alexander
mesh_terms: D001834:Body Water / Q000378:metabolism; D002199:Capillary Permeability; D016207:Cytokines / Q000097:blood*; D005110:Extracellular Space / Q000378:metabolism; D006440:Hemofiltration; D006801:Humans; D006820:Hyaluronic Acid / Q000378:metabolism; D008567:Membranes, Artificial; D018805:Sepsis / Q000097:blood / Q000628:therapy*
chemical_list: D016207:Cytokines; D008567:Membranes, Artificial; D006820:Hyaluronic Acid